Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, incorporated in Ireland, filed this Current Report on April 21, 2015. The filing announces the release of earnings results for the third quarter of fiscal 2015. The report includes a press release (Exhibit 99.1) detailing financial performance and non-GAAP reconciliations.
Key Financial Metrics
This Form 8-K serves as a notification of the earnings release and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing states that the attached press release contains the detailed financial data, including reconciliations for Cost of sales, Gross profit, Operating income, Net income, and Earnings per share.
Material Changes and Non-GAAP Adjustments
Management utilizes adjusted financial data to evaluate core business operations by excluding specific non-core items. The filing lists the following exclusions for the relevant periods:
- Fiscal 2014 (Q3 and YTD): Amortization of acquired intangibles, restructuring charges, acquisition/integration charges, contingent consideration write-offs, escrow settlements, in-process R&D write-offs, transaction/debt extinguishment charges, litigation settlements, and losses on equity/investment sales.
- Fiscal 2015 (Q3 and YTD): Amortization of acquired intangibles, restructuring charges, R&D payments for collaborative arrangements, acquisition/integration charges, financing/debt extinguishment charges, derivative losses on acquisition hedging, equity method investment losses, income from rights transfers, share issuance effects, investment distributions, and increased litigation accruals.
Guidance, Outlook, and Risks
The Company provided non-GAAP guidance for calendar 2015, which excludes amortization of intangibles, restructuring, unusual litigation charges, and transaction/financing costs related to the Omega Pharma Invest NV ("Omega") acquisition. A reconciliation to GAAP guidance for calendar 2015 is not available without unreasonable effort at this time.
Significant Risks and Contingencies:
- Acquisition Impact: Unavailable reconciling items, primarily related to Omega amortization and integration expenses, could significantly impact financial results.
- Fiscal Year Change: The Company is undergoing a change in its fiscal year.
- Takeover Indication: There is a recent indication of interest for the acquisition of Perrigo Company plc.
- Disclosure Obligations: Persons interested in 1% or more of securities of Perrigo or Mylan N.V. may have disclosure obligations under Irish Takeover Rules.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific GAAP and non-GAAP financial figures for Q3 Fiscal 2015.
- Verify the reconciliation tables provided in the press release to understand the magnitude of excluded items (e.g., Omega acquisition costs, restructuring).
- Assess the impact of the "indication of interest" for the acquisition of the Company on future operations and stock price.
- Monitor the timeline and financial implications of the Company's change in fiscal year.
- Confirm the status of the Omega Pharma integration and associated non-cash charges.